Niagen Bioscience presents results in journal Aging Cell

Niagen Bioscience (NAGE) shared results from a clinical study published in the peer-reviewed journal Aging Cell. This is the first study to demonstrate the safety and efficacy of Niagen Bioscience’s patented nicotinamide riboside ingredient, Niagen, in individuals with Werner syndrome, a rare genetic disorder marked by rapid aging and premature mortality. The newly published double-blind, placebo-controlled study found that daily supplementation with Niagen significantly elevated blood NAD+ levels by approximately 140% and improved multiple clinical markers of cardiovascular and skin health in individuals with WS.